Åsa Wallin
21 – 30 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Three-year outcome of rivastigmine treatment in Alzheimer's disease in a routine clinical setting.
2013) 11th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2013)(
- Contribution to conference › Poster
-
Mark
Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.
(
- Contribution to journal › Article
- 2012
-
Mark
Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
(
- Contribution to journal › Article
-
Mark
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia.
(
- Contribution to journal › Article
-
Mark
Alzheimer’s disease with normal CSF biomarkers.
2012) 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
- 2011
-
Mark
Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment.
(
- Contribution to journal › Article
-
Mark
Risk Factors for Nursing Home Placement in Alzheimer's Disease: A Longitudinal Study of Cognition, ADL, Service Utilization, and Cholinesterase Inhibitor Treatment.
(
- Contribution to journal › Article
-
Mark
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Predictors of long-term cognitive outcome in Alzheimer's disease.
(
- Contribution to journal › Article